GSE123699
RNA-seq of iPSC-ECs treated under normoglycemic and hyperglycemic conditions with and without MDL-28170 treatment
Two healthy iPSC lines were differentiated into ECs. iPSC-ECs were then treated under normoglycemic (5.5mM glucose) or hyperglycemic (33mM glucose) conditions with and without MDL-28170 (2.5 uM) for 72 hours. Overall design: RNA-seq of iPSC-ECs under normoglycemia or hyperglycemia; with and without calpain inhibition (MDL-28170) over a period of 72 hours.